FIG 2.

(A) OS by predefined subgroups with nivolumab plus ipilimumab versus placebo and (B) nivolumab monotherapy versus placebo. ^aNot reported for three patients in the nivolumab plus ipilimumab arm, four patients in the nivolumab arm, and three patients in the placebo arm. ^bNot evaluated for one patient in the placebo arm. CR, complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; LDH, lactate dehydrogenase; OS, overall survival; PCI, prophylactic cranial irradiation; PR, partial response; SD, stable disease; ULN, upper limit of normal.